Caplin Point Laboratories · NSE: CAPLIPOINT · BSE: 524742
Q4 FY24 results · Jan–Mar 2024
Caplin Point Laboratories reported revenue from operations of ₹453.22 crore (up 16.4% from Q4 FY23) and net profit of ₹121.23 crore (up 19.7% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 453.22 | 389.28 | +16.4% | 435.50 | +4.1% |
| Other income | 17.29 | 11.40 | +51.7% | 17.18 | +0.6% |
| Total income | 470.51 | 400.68 | +17.4% | 452.68 | +3.9% |
| Profit before tax | 146.03 | 124.05 | +17.7% | 145.38 | +0.4% |
| Net profit for the period | 121.23 | 101.24 | +19.7% | 119.83 | +1.2% |
| Attributable to shareholders of the company | 121.59 | 102.11 | +19.1% | 117.20 | +3.7% |
| EPS, basic (₹) | 16.01 | 13.45 | +19.0% | 15.44 | +3.7% |
| Net margin (%) | 26.7 | 26.0 | 27.5 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 139.38 | 144.67 | −3.7% | 132.83 | +4.9% |
| Other income | 36.18 | 12.22 | +196.1% | 17.90 | +102.2% |
| Total income | 175.56 | 156.89 | +11.9% | 150.73 | +16.5% |
| Profit before tax | 86.91 | 70.77 | +22.8% | 74.43 | +16.8% |
| Net profit for the period | 69.88 | 54.33 | +28.6% | 55.45 | +26.0% |
| EPS, basic (₹) | 9.20 | 7.15 | +28.7% | 7.30 | +26.0% |
| Net margin (%) | 50.1 | 37.6 | 41.7 |
Consolidated
- Filed with BSE
- 17 May 2024, 15:34 IST
- Board meeting
- 16 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 May 2024, 15:34 IST
- Board meeting
- 16 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE